Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Pain, Postoperative 1Pain 1Multiple Myeloma 1Lymphoma 1

Interventions

pembrolizumab 9Nivolumab 7cemiplimab 6Ipilimumab 6Blood Specimen Collection 3lifileucel 2encorafenib 2binimetinib 2aldesleukin 2Niacinamide 2Cyclophosphamide 2toripalimab 1tislelizumab 1relatlimab 1oxycodone-acetaminophen 1lenvatinib 1lavender oil 1fludarabine 1epacadostat 1durvalumab 1dostarlimab 1brodalumab 1avelumab 1atezolizumab 1Water 1Vitamin A 1Tissue Banks 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × oxycodone-acetaminophen × 90 days × Clear all
NCT07575230 2026-05-11

Suzetrigine vs Norco-postoperative Mohs Pain

Baylor Research Institute

Phase 4 Enrolling by invitation
75 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡